

Meta-analysis study of the therapeutic impact of Mesenchymal stem cells derived exosomes for chronic kidney diseases

Himanshu k^{1, 2†}, Gunjan k^{1, 2†}, Ramendera Pati Pandey³, Riya Mukherjee^{1, 2}, Chung-Ming Chang^{2, 4*}

¹Graduate Institute of Biomedical Sciences, Chang Gung University, No. 259, Wenhua 1st Road, Guishan District Taoyuan city 33302, Taiwan (R.O.C).

²Master & Ph.D. Program in Biotechnology Industry, Chang Gung University, No. 259, Wenhua 1st Road, Guishan District Taoyuan city 33302, Taiwan (R.O.C).

³School of Health Sciences and Technology (SoHST) UPES, Bidholi, Dehradun, 248007, Uttarakhand, India.

⁴Department of Medical Biotechnology and Laboratory Science, Chang Gung University, No. 259, Wenhua 1st Road, Guishan District Taoyuan city 33302, Taiwan (R.O.C).

†: These authors contributed equally.

Correspondence: cmchang@mail.cgu.edu.tw (C.M.C)

Abstract

Mesenchymal stem cell-derived exosomes (EXOs) represent a promising avenue for treating chronic kidney diseases (CKD), though their precise impact remains somewhat elusive. To address this gap, we conducted a systematic analysis, scouring databases and clinical trial repositories for relevant studies from 2019 to 2023. Seventeen papers were meticulously selected for their focus on mesenchymal stem cell-derived exosomes (MSC-EXOs) and their potential in CKD treatment. Our comprehensive meta-analysis, incorporating 15 preclinical and 6 clinical studies, underscores the efficacy of MSC-EXOs in improving renal function while attenuating tubular injury, inflammation, apoptosis, collagen deposition, and renal fibrosis. Notably, post-treatment with MSC-EXOs exhibited significant associations with various CKD markers, with pooled proportions indicating a considerable impact on blood urea nitrogen (BUN) and serum creatinine (SCR) levels. Subgroup analyses based on animal models further elucidated heterogeneity within the studies. In conclusion, MSC-EXOs demonstrate promise in enhancing renal function and reducing CKD risk, as evidenced by both preclinical and clinical data. Their efficacy in lowering SCR and BUN levels while enhancing filtration rate suggests MSC-EXOs as a viable and secure alternative to cell-based therapies, thereby providing valuable insights for personalized CKD treatments despite inherent limitations.

Keywords: Mesenchymal stem cells, Exosome, Chronic Kidney Diseases, Renal fibrosis.

Introduction

Chronic kidney disease (CKD) emerges as a significant global health concern that demands attention. It is elevated incidence, substantial healthcare burden, insidious onset, poor prognosis, and other associated challenges pose serious threats to the well-being of individuals worldwide[1, 2]. CKD emerges because of diminished oxygen delivery to the kidneys. Subsequent amplification of kidney hypoxia leads to compromised regenerative capacity, cell damage, oxidative stress, eliciting inflammatory responses and renal fibrosis within the kidney compartments[3]. To counteract these processes, numerous pharmaceutical therapies have been developed. There are five phases of CKD, and each one is linked to increased risks of cardiovascular morbidity, early mortality, and/or a poor standard of life[4]. Renal damage, indicative of CKD, encompasses pathological abnormalities, abnormal urine sediment, or an elevated urinary albumin excretion rate, detectable through imaging or renal biopsy[5]. Currently, none of these therapies have been clinically validated to effectively alter the outcome of CKD. [6–8]. By the year 2040, it is projected to become the fifth most prevalent cause of death globally[9]. Unfortunately, conventional pharmacological methods often overlook the intricate interconnections and complexities of overlapping disease-related mechanisms[10]. An alternate approach including targeted delivery and control of disease pathways through the transfer facilitated by extracellular vesicles (EVs) could address the bottleneck between regenerative medicine and current pharmaceutical treatments.[11].

According to recent data, CKD is a global health issue, affecting approximately 9% to 13% of the worldwide population (approximately 700 million to one billion people), with a significant portion of patients falling into stage 3 of the disease.[4, 5, 13]. It rates up to 15% in the USA, that is about 37 million people, causing a high economic burden[13]. Tragically, millions of individuals die each year due to the lack of affordable treatment options. The 2023 ISN-GKHA report highlights the widespread impact of CKD, with around 850 million people affected globally, regardless of age[14]. Disadvantaged populations are particularly vulnerable to the disease. The high costs of treatment and the significant health consequences associated with kidney disease contribute to its devastating effects. In Taiwan, CKD has become a major concern, ranking as the 9th leading cause of death over the past decade[15]. Research estimates that the national prevalence of CKD in Taiwan is approximately 11.9%, affecting more than 2.5 million people[16, 17]. Furthermore, Taiwan has a more than 1.5-fold

greater prevalence of end-stage renal disease (ESRD) than the United States, with approximately 3400 individuals per 1 million in the general population experiencing kidney failure[18]. These statistics highlight the urgent need for improved access to affordable treatment options and increased awareness about CKD worldwide.

In recent years, cell-based therapies have garnered attention across various medical research fields. Mesenchymal stromal cells (MSCs) are extracted from diverse adult tissues, including adipose tissue, umbilical cord blood, bone marrow, and macrophage[19] MSCs are multipotent cells that can differentiate into tissues derived from mesoderm and have the ability to self-renew. [20]. Furthermore, MSC possesses the ability to evade alloantigen recognition owing to their low immunogenicity and lack of expression of co-stimulatory molecules. The inherent immunomodulatory properties of MSCs, coupled with their minimal potential side effects, present a therapeutic alternative in this regard[21]. Recent studies suggest that administration of MSC-derived EVs ameliorates CKD in preclinical models. [22–25].

In the realm of renal diseases, EXO derived from MSC have gained significant attention due to their pathophysiological, diagnostic, and therapeutic roles [26]. These nanosized vesicles, ranging from 30 to 100 nm in diameter, originate from multivesicular bodies [27]. Under both physiological and pathological conditions, various cell release EXO into the blood or other bodily fluids, reflecting cellular responses to internal and external stimuli [28]. EXO carry a diverse cargo, including proteins, long noncoding RNAs, microRNAs (miRNAs), mRNAs, and lipids of particular note, miRNAs, which are noncoding, single-stranded small RNAs, which play a vital part in regulating gene expression by binding to the 3' untranslated regions (UTRs) of target mRNAs, which leads to disintegration or translational suppression. [29, 30]. Preclinical studies have showcased the positive impacts of MSC-derived EVs ameliorates CKD derived from cells, including secreted growth factors, microvesicles, and EXO, in models of chronic kidney injury[31]. These findings suggest a regenerative influence of cell-based therapies on renal function. Additionally, MSCs are actively employed in several clinical trials involving kidney transplant recipients, with the goal of enhancing immunosuppression and promoting improved regeneration [32]. Additionally, these EXO are free from the adverse aspects related to tumorigenic and immunogenic associated with cellular therapies, making them a safer and more viable avenue for future regenerative medicine [33].

In this meta-analysis and systematic review aimed to assess the impact of MSC derived EXO on outcome parameters related to chronic kidney disease function and morphology, scrutinizing both cell- and model-related aspects. The existing studies can enhance the design of future clinical investigations. Additionally, the insights gained can be utilized to refine current experimental animal models and interventions, thereby improving the quality of preclinical research in the future.

Result

Study selection and characteristics

A total of 758 papers published from 2019 to 2023 were systematically categorized using esteemed databases, including PubMed (n = 186), Web of Science (n = 95), Google Scholar (n = 402), and Cochrane (n = 56), along with 19 additional records sourced from other sources. Out of these categorized articles 427 duplicate articles were removed, within this selected, 331 articles 224 articles were excluded due to reasons such as their classification as review articles (89), conference papers (17), case reports (76), book chapters (26), and abstracts (16). Our meticulous screening process meticulously refined the dataset to 107 studies suitable for our systematic review. This subset underwent further scrutiny, resulting in the exclusion of 94 articles. These exclusions were attributed to diverse reasons, including publications in languages other than english (3), inappropriate study designs (38), and absence of extracellular vesicle (EV) administration in treatment (23), unsuitable outcomes (7), and unrepresentative results (19). This exhaustive evaluation ultimately led to the inclusion of 17 pre-clinical studies [34–50] that met our stringent inclusion criteria. The study selection process adhered to the PRISMA[51] flow diagram, as shown in figure 1.

Quality assessment

The risk of bias assessment for the included studies reveals variations in specific domains. Xi Liu et al [44], Yingjie Liu et al. [36] and H. Wang et al.[52] is deemed to have a high risk of incomplete outcome data (attrition bias), indicating potential concerns regarding the completeness of outcome data reported in this study. Conversely, M. Liang et al. [53], and Yan Wang et al. [42] and H. Wang et al. [52] are characterized by a low risk of baseline characteristics and other bias, suggesting that the methods used to assess and measure outcomes in these studies are robust and unlikely to introduce bias, as shown in figure 2.

General characteristics

Clinical

CKD is a multifaceted and advancing health issue, often requiring a range of treatments and approaches. One area of promising exploration involves EXO, which has emerged for their potential therapeutic impact on CKD. To determine the efficacy and safety of employing EXO-based therapies for CKD, numerous clinical trials have been carried out. These trials encompass a spectrum of EXO sourced from different origins, such as MSCs, bone marrow, adipose tissue, umbilical cord, and various other cell types. The diversity in exosome sources is aimed at understanding their distinct compositions and potential roles in alleviating CKD-related complications.

To the best of our current knowledge, there are no registered clinical trials for the treatment of CKD using exosomes on clinicaltrials.gov. However, we have compiled a list of ongoing clinical trials that explore the therapeutic potential of MSCs for diverse medical conditions. These trials exhibit a varied landscape in terms of clinical status, phases, locations, study types, sources of EXO, and study durations. Among the six trials with known clinical status, one has been completed (NCT02166489), four are actively recruiting (NCT05512988, NCT03939741), and NCT05362786 is active but not recruiting, while the status of the remaining two is unknown (NCT03321942, NCT05042206). These trials encompass both allogeneic and autologous approaches, with three employing allogeneic MSCs, three using autologous MSCs, and one unspecified. In terms of phases, three trials are in Phase I, two are in Phase I/II, and one does not specify its phase. Geographically, the trials are spread across different countries, including one in the United States, China, Iran, Korea, and Bangladesh. The MSC used in these trials primarily originates from bone marrow ($n = 3$), followed by adipose tissue ($n = 2$) and umbilical cord ($n = 1$), as summarized in table 1.

Pre-clinical

This meta-analysis and systematic review meticulously explore exosome-based therapeutic interventions for chronic kidney disease (CKD) through a comprehensive analysis of diverse sources. The study encompasses data from various animal models, including C57BL/6 ($n=9$), SD rats ($n=4$), BALB/c ($n=2$), Albino rats ($n=1$), and Bred Fisher rats ($n=1$), originating from countries such as the USA ($n=2$), China ($n=13$), Saudi Arabia ($n=1$), and South Korea ($n=1$). The investigation includes a gender-specific breakdown, focusing on human ($n=11$) and animal ($n=17$) subjects, and incorporates a variety of cell types, such as human umbilical cord MSC (hucMSCs) ($n=3$), human bone marrow-derived MSCs (BM-MSC) ($n=4$), adipose

tissue-derived MSC (n=1), among others. Diverse exosome isolation methods are examined, comprising ultracentrifugation (n=8), centrifugation + filtration (n=7), and exosome isolation kits (n=2). Characterization techniques involve nanoparticle tracking analysis (NTA) (n=2), transmission electron microscopy (TEM) (n=5), both TEM and NTA (n=9), and N/A (n=1). The study identifies a consistent EXO size range of 30 to 150 nm, with common markers CD9, CD63, and TSG101. Administration routes vary, including intravenous (n=14), intramuscular (n=1), intraperitoneal (n=1), and intracellular (n=1), with concentrations ranging from 20 mg to 250 µg, providing a thorough overview of EXO -based therapies in managing CKD. At the culmination of this analysis, these findings underscore the diverse landscape of EXO -based therapies in addressing CKD, offering valuable insights into the potential efficacy and methodologies employed across various studies, aiming to elucidate optimal strategies for leveraging EXO therapy in CKD management, as summarized in table 2.

Meta-analysis

A. Primary outcome

i. Blood urea nitrogen (BUN)

BUN is a waste product that is produced when protein is broken down in the body[54]. The analysis of BUN in CKD reveals a notable degree of heterogeneity, as indicated by an I^2 value of 92%, τ^2 of 0.0573%, and a significant p-value of less than 0.01. This substantial heterogeneity underscores the diversity in BUN outcomes across the studies included in the review. The calculated proportion and its 95% confidence interval (CI) further emphasize this variability, with a value of 0.55 [0.41; 0.68], as depicted in figure 3A.

ii. Serum creatinine (SCR)

SCR is a waste product that is produced when creatinine, a chemical that is found in muscle tissue, is broken down[54]. In the context of CKD, the analysis of SCR levels reveals a high degree of heterogeneity, as evidenced by an I^2 value of 98%, τ^2 of 0.0649%, and a significant p-value of less than 0.01. This substantial heterogeneity underscores the varied outcomes observed across studies included in the analysis. The calculated proportion and its 95% CI further emphasize this diversity, with the value of 0.64 [0.52; 0.77], as depicted in figure 3B.

B. Secondary outcome

i. Animal model subgroup analysis based on BUN level

In the evaluation of BUN in animal models of CKD, notable heterogeneity is observed across various species. Among C57BL/6 mice, there is a significant degree of heterogeneity with an I^2 value of 93%, τ^2 of 0.0504%, and a p-value less than 0.01. The proportion estimate, with its 95% CI, is calculated at 0.62 [0.45; 0.79], with this animal model contributing 56.0% of the overall weight. Similarly, SD rats exhibit high heterogeneity (I^2 : 93%, τ^2 : 0.1122%, $p < 0.01$), with a proportion estimate of 0.54 [0.14; 0.94] and contributing 20.0% to the overall analysis. Bred Fisher rats, on the other hand, demonstrate a proportion estimate of 0.67 [0.36; 0.77], representing 5.6% of the total weight. BALB/c mice display substantial heterogeneity (I^2 : 86%, τ^2 : 0.0820%, $p < 0.01$), with a proportion estimate of 0.58 [0.15; 1.00] and contributing 13.8% to the overall analysis. Albino rats exhibit a proportion estimate of 0.59 [0.47; 0.72], accounting for 4.6% of the total weight. In aggregate, there remains significant heterogeneity across all models (I^2 : 94%, τ^2 : 0.0495%, $p < 0.01$), with an overall proportion estimate of 0.59 [0.47; 0.72], as depicted in figure 4A.

ii. Animal model subgroup analysis based on SCR level

In the investigation of SCR levels across various animal models of CKD, significant heterogeneity is observed. Among C57BL/6 mice, a high degree of heterogeneity is evident with an I^2 value of 97%, tau square of 0.0623%, and a p-value less than 0.01. The proportion estimate, accompanied by its 95% CI, is determined to be 0.65 [0.47; 0.82], with this animal model contributing 49.8% to the overall weight. Similarly, SD rats display pronounced heterogeneity (I^2 : 99%, τ^2 : 0.1190%, $p < 0.01$), with a proportion estimate of 0.56 [0.22; 0.90] and representing 24.9% of the total weight. Bred Fisher rats, in contrast, exhibit a proportion estimate of 0.73 [0.59; 0.84], contributing 6.2% to the overall analysis. BALB/c mice demonstrate substantial heterogeneity (I^2 : 99%, τ^2 : 0.1236%, $p < 0.01$), with a proportion estimate of 0.75 [0.26; 1.00] and contributing 12.8% to the overall weight. Albino rats display a proportion estimate of 0.66 [0.52; 0.76], accounting for 6.2% of the total weight. Collectively, significant heterogeneity persists across all models (I^2 : 98%, τ^2 : 0.0649%, $p < 0.01$), with an overall proportion estimate of 0.64 [0.52; 0.77], as depicted in figure 4B.

Discussion

In this comprehensive systematic review and meta-analysis, encompassing 17 preclinical and 6 clinical studies, we provide a thorough examination of the impact of MSC-EXOs on diverse models of CKD. Preclinical and clinical studies have demonstrated that treating patients with CKD using MSC-EXOs leads to reductions in SCR and BUN levels, improved glomerular

filtration rate, and protection of renal functions, along with the suppression of inflammatory responses. Though our knowledge of the distinct parts of vesicular structures, their specific functions, and their roles as therapeutic vectors, biomarkers, and contributors to autoimmune disorders is still insufficient. The exploration of EXOs in CKD pathogenesis is still in its early stages, with limited research compared to other diseases. Further research is essential for the clinical application of MSC-EXOs. Although the safety of MSC-EXOs has been initially confirmed through animal experiments, extensive studies are required to ensure their safety for clinical use. Various MSC sources, such as bone marrow, adipose tissue and umbilical cord, contribute to EXOs derivation, necessitating additional experiments to assess the safety of different MSC- EXOs.

The delivery of EXOs has various benefits as a cell-free therapeutic approach, such as enhanced stability, reduced immunogenicity, permeability, and cytotoxicity[55]. As a result, employing EXOs could offer a practical and secure substitute for cell-based treatments. Many studies attribute these beneficial effects primarily to the RNA cargo carried by EVs, and it's noteworthy that these effects can be abrogated by RNase treatment. Numerous miRNA candidates, such as miR29, miR-294/miR-133, miR-26a, and miR-374a-5p, have been implicated in the pathophysiological processes of CKD. Research has revealed specific mechanisms through which various miRNAs contribute to mitigating kidney fibrosis and related complications in CKD. For instance, miR29 has been shown to ameliorate skeletal muscle atrophy and diminish kidney fibrosis by suppressing YY1 and proteins involved in the TGF- β pathway [50]. Additionally, by blocking the phosphorylation of SMAD2/3 and ERK1/2, miR-294/miR-133 has shown promise in preventing TGF- β 1-induced epithelial-mesenchymal transition in HK2 cells [42]. Moreover, downregulation of miR-26a expression has been associated with reduced tubular injury and tubulointerstitial fibrosis induced by aldosterone[40]. Furthermore, miR-374a-5p has been shown to impede the progression of renal fibrosis by modulating the MAPK6/MK5/YAP axis, ultimately leading to reductions in urea and creatinine levels [38].

Beyond the influence of microRNAs, various therapeutic interventions involving MSCs and their derivatives have demonstrated promising outcomes in combating renal fibrosis and CKD. For instance, EXO derived from tubules play a role in promoting renal fibrogenesis by transporting the Sonic Hedgehog ligand [46]. HucMSC-ExO have demonstrated effectiveness in reducing renal fibrosis induced by UUO and preventing tubular cell apoptosis by inhibiting the ROS-mediated p38MAPK/ERK signaling pathway [45]. Additionally, it has been

demonstrated that modified EXO employing heparin-chitosan MHCD reduces renal fibrosis in rats suffering from IgA nephropathy by inhibiting the TGF- β 1/Smad3 pathway by lowering TGF- β 1 expression in the EXO cargo [39]. Moreover, anti-let-7i-5p treatment with BM-MSCs has been effective in countering TGF- β 1-induced fibrosis in NRK52E cells and inhibiting UUO-induced renal fibrosis *in vivo* [48]. PSC-MSCs-derived EXO have shown the ability to upregulate SIRT6 expression while downregulating β -catenin and its downstream products [49]. Additionally, BM-MSC-derived EXO have enhanced the protective effects against TGF- β 1-induced fibrosis when combined with si-Smurf2 [36]. BM-MSCs EXOs have further demonstrated their impact on hindering CKD progression by lowering the gene expression of NGAL, TGF- β 1, and α -SMA [37]. In co-culture experiments, TGF- β -induced tubular epithelial cells with macrophages led to M1 polarization, whereas BM-MSC EXO from TECs without TGF- β or with TGF- β alone did not induce M1 macrophage markers [34]. HucMSC-derived EXOs have shown a reduction in pyroptosis-related proteins (IL-1 β , NLRP3, caspase-1, and GSDMD) in renal tissue of rats with ischemia-reperfusion injury (IRI) [35]. Furthermore, EXOs from HKC-8 cells, when treated with TNFAIP8, promoted fibroblast survival by inducing p53 degradation and stimulating proliferation [44, 47]. Additionally, in mouse tubular epithelial cells, quercetin has been identified to inhibit EXOs release, exerting reno-protective effects by suppressing Hsp70 or Hsp90 [43]. These diverse strategies involving MSCs-EXO and their derivatives showcase their potential in addressing various aspects of renal fibrosis and CKD progression.

Understanding the specific study design and factors influencing the efficacy of EXOs based treatments can enhance the planning of future experimental studies and aid in designing studies for specific patient populations. Accordingly, for studies with available creatinine (SCR) and urea data (BUN), we conducted uni-variable stratified meta-analyses to explore potential predictors for EXO-based therapy effectiveness across diverse CKD settings. To elucidate the impact of EXO treatment on various animal models, we conducted subgroup analysis graphs. Our findings indicate that the functional efficacy of EXO therapy varies depending on the model employed. Notably, a significant proportion of the animal records analyzed in our study pertained to CKD models.

As a cell-free therapeutic approach, EXO present numerous advantages, characterized by high stability and permeability, as well as low immunogenicity and cytotoxicity [56]. This suggests that the administration of EXOs could serve as a viable and safe alternative to cell-based therapies. Despite this potential, it's important to acknowledge substantial

heterogeneity in the literature, and even after conducting subgroup analysis, this heterogeneity persisted.

In summary, MSC-EXOs demonstrate promise in improving renal function and mitigating the risk of CKD. Our findings, supported by both preclinical and clinical evidence, confirm the efficacy of MSC-EXOs in lowering SCR and BUN levels, enhancing glomerular filtration rate, and alleviating renal inflammation within a rodent model of CKD. This study suggests that EXOs could serve as a secure alternative to cell-based therapies. The prospects involve addressing current challenges, conducting clinical trials, standardizing protocols, and advancing our understanding of EXO-based therapies to pave the way for their effective clinical implementation in the management of CKD. This work paves the way for future studies to contribute to the development of advanced therapies for CKD and underscores the potential for growth and innovation in the biopharmaceutical sector

Materials and methods

a. Literature search

For our present study, we conducted a comprehensive search across multiple databases, including Google scholar, PubMed/MEDLINE, Scopus, EMBASE, and the Web of Science, CINAHL, the Cochrane Register for Controlled Trials (CENTRAL), LILACS, SciELO, etc. with a focus on studies related to EXO-mediated treatment of CKD. The latest search update was performed on January 31, 2024. The search strategy involved employing various combinations of keywords, such as (“extracellular vesicle” OR “EV” OR “exosome”) AND (“stromal cell” OR “stem cell” OR “SC” OR “mesenchymal stem cell” OR “MSC”) and (“kidney disease” OR “kidney dysfunction” OR “chronic kidney disease” OR “renal Fibrosis” OR “Chronic Renal Failure” OR “chronic renal insufficiency” OR “CKD” OR “renal dysfunction”). We assessed study quality using defined criteria from the Collaborative Approach to Meta-analysis and Review of Animal Data in Experimental Studies (CAMRADES) risk of bias checklist. Moreover, for clinical studies, we conducted a thorough data search utilizing a comprehensive database encompassing privately and publicly funded clinical trials conducted globally, available at <https://clinicaltrials.gov/>. Additionally, manual searches of bibliographies and reference lists were performed to identify any additional relevant studies. No ethical approval was required as the meta-analysis relied solely on published articles.

b. Inclusion criteria

Following the elimination of duplicates, the articles were screened using the predetermined inclusion and exclusion criteria. Inclusion criteria encompassed: (1) original articles; (2) animal experiments utilizing rats, mice etc.; (3) focus on chronic kidney fibrosis or renal fibrosis; (4) intervention involving the injection of EVs derived from any MSC source; (5) EXOs obtained from either stem cells or pluripotent cells, with a specific emphasis on CKD, and mandated the inclusion of at least one group subjected to EXO treatment.; (6) preconditioned, and modified MSC-EXOs (such as those transfected with genes or featuring overexpression of proteins or microRNAs) were encompassed in the study. (7) administration of MSC-EXOs involved either allogeneic, xenogeneic or autologous approaches. and (8) assessment of therapeutic efficacy as the outcome.

c. Exclusion criteria

Exclusion criteria involved: (1) studies lacking a control group or involving inappropriate comparisons; (2) those not focusing on CKD models; (3) research combining therapeutic approaches with other agents of uncertain effects; and (4) article types such as comments, letters, reviews, editorials, and case reports, and (5) animal model used for other kidney related disorders, such as acute kidney disease, stroke and kidney stone formation.

d. Data extraction

Data extraction from all eligible studies encompassed gathering the following information for the clinical trials table: authors' names, study location, status of the trials, study year, type of kidney disease, study type, phase, patients' number, autologous/allogeneic, administration, frequency, outcome measures and intervention findings. Similarly, the preclinical trials table was compiled using the following details: author's name, country, publication year, animal model and their sex, human or animal derived, EXO source, isolation methods, modified strategy, and outcomes. Additionally, another data was compiled in a table by using information such as: author's name, characterization techniques, EXO size, induction methods, concentration, time of EXO administration and end point of the study. Spreadsheets were created to facilitate the extraction and synthesis of the data by using Excel® (Microsoft® Office Excel 2021) and subjected to pre-testing before complete extraction. Citations from the compiled papers were managed using Mendeley software (version 2.105.0, Elsevier, London, UK).

e. Quality assessment

Assessing publication bias is crucial to ensuring the integrity and credibility of the meta-analysis focused on the effects of EXOs on various aspects of CKD. To gauge the potential impact of publication bias in our findings, we applied several established techniques widely recommended in the field. A key method involved visually inspecting a bias risk graph for asymmetry, which may indicate the presence of publication bias. By employing these comprehensive approaches, our goal was to systematically address any potential bias and guarantee that our meta-analysis offers an unbiased synthesis of the current evidence regarding the positive effects of EXOs in the context of CKD.

f. Statistical analysis

The study compiled data on CKD, EXO source, and group sizes from papers or correspondence with authors. Employing random-effects models in meta-analysis, individual effects were considered, avoiding fixed effects to effectively address unobserved heterogeneity. Results were presented using effect size and 95% CI. The metafor package in R (<https://www.R-project.org/>) facilitated all analyses. Notably, the meta-analysis specifically targeted SCR and BUN levels within the study.

Declaration of Interests: The authors declare that they have no competing interests.

Ethics approval and consent to participate: 'Not applicable'

Consent for publication: All authors have given their consent to publish

Availability of data and materials: The authors confirm that the data supporting the findings of this study are available within the article.

Competing interests: None

Funding: VtR Inc-CGU (SCRPD1L0221); DOXABIO-CGU (SCRPD1K0131), and CGU grant (UZRPD1L0011, UZRPD1M0081).

Authors' contributions: All authors have equally contributed to the conceptualization, methodology, and writing and editing of the manuscript.

Acknowledgements: This research was funded by VtR Inc-CGU (SCRPD1L0221); DOXABIO-CGU (SCRPD1K0131), and CGU grant (UZRPD1L0011, UZRPD1M0081). We have not used AI in the preparation of the manuscript.

References

1. Cockwell, P., Fisher, L.A.: The global burden of chronic kidney disease. *The Lancet*. 395, 662–664 (2020). [https://doi.org/10.1016/S0140-6736\(19\)32977-0](https://doi.org/10.1016/S0140-6736(19)32977-0)
2. Kovesdy, C.P.: Epidemiology of chronic kidney disease: an update 2022. *Kidney Int Suppl* (2011). 12, 7 (2022). <https://doi.org/10.1016/J.KISU.2021.11.003>

3. Nowak, N., Yamanouchi, M., Satake, E.: The Nephroprotective Properties of Extracellular Vesicles in Experimental Models of Chronic Kidney Disease: a Systematic Review. *Stem Cell Rev Rep.* 18, 902–932 (2022). <https://doi.org/10.1007/S12015-021-10189-9/TABLES/2>
4. Hill, N.R., Fatoba, S.T., Oke, J.L., Hirst, J.A., O’Callaghan, C.A., Lasserson, D.S., Hobbs, F.D.R.: Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. *PLoS One.* 11, e0158765 (2016). <https://doi.org/10.1371/JOURNAL.PONE.0158765>
5. Li, J., Ma, L., Yu, H., Yao, Y., Xu, Z., Lin, W., Wang, L., Wang, X., Yang, H.: MicroRNAs as Potential Biomarkers for the Diagnosis of Chronic Kidney Disease: A Systematic Review and Meta-Analysis. *Front Med (Lausanne).* 8, 782561 (2022). <https://doi.org/10.3389/FMED.2021.782561/BIBTEX>
6. Breyer, M.D., Susztak, K.: Developing Treatments for Chronic Kidney Disease in the 21st Century. *Semin Nephrol.* 36, 436–447 (2016). <https://doi.org/10.1016/J.SEMNEPHROL.2016.08.001>
7. van der Pol, E., Böing, A.N., Gool, E.L., Nieuwland, R.: Recent developments in the nomenclature, presence, isolation, detection and clinical impact of extracellular vesicles. *Journal of Thrombosis and Haemostasis.* 14, 48–56 (2016). <https://doi.org/10.1111/JTH.13190>
8. Ix, J., Shlipak, M.: Trial of Pirfenidone to Prevent Progression of Chronic Kidney Disease (TOP?CKD).
9. Foreman, K.J., Marquez, N., Dolgert, A., Fukutaki, K., Fullman, N., McGaughey, M., Pletcher, M.A., Smith, A.E., Tang, K., Yuan, C.W., Brown, J.C., Friedman, J., He, J., Heuton, K.R., Holmberg, M., Patel, D.J., Reidy, P., Carter, A., Cercy, K., Chapin, A., Douwes-Schultz, D., Frank, T., Goettsch, F., Liu, P.Y., Nandakumar, V., Reitsma, M.B., Reuter, V., Sadat, N., Sorensen, R.J.D., Srinivasan, V., Updike, R.L., York, H., Lopez, A.D., Lozano, R., Lim, S.S., Mokdad, A.H., Vollset, S.E., Murray, C.J.L.: Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. *The Lancet.* 392, 2052–2090 (2018). [https://doi.org/10.1016/S0140-6736\(18\)31694-5](https://doi.org/10.1016/S0140-6736(18)31694-5)
10. Ruiz-Ortega, M., Rayego-Mateos, S., Lamas, S., Ortiz, A., Rodrigues-Diez, R.R.: Targeting the progression of chronic kidney disease. *Nature Reviews Nephrology* 2020 16:5. 16, 269–288 (2020). <https://doi.org/10.1038/s41581-019-0248-y>
11. O’Brien, K., Breyne, K., Ughetto, S., Laurent, L.C., Breakefield, X.O.: RNA delivery by extracellular vesicles in mammalian cells and its applications. *Nature Reviews Molecular Cell Biology* 2020 21:10. 21, 585–606 (2020). <https://doi.org/10.1038/s41580-020-0251-y>
12. Sundström, J., Bodegard, J., Bollmann, A., Vervloet, M.G., Mark, P.B., Karasik, A., Taveira-Gomes, T., Botana, M., Birkeland, K.I., Thuresson, M., Jäger, L., Sood, M.M., VanPottelbergh, G., Tangri, N.: Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2.4 million patients from 11 countries: The

- CaReMe CKD study. *The Lancet Regional Health - Europe*. 20, 100438 (2022). <https://doi.org/10.1016/j.lanepe.2022.100438>
13. Sundström, J., Bodegard, J., Bollmann, A., Vervloet, M.G., Mark, P.B., Karasik, A., Taveira-Gomes, T., Botana, M., Birkeland, K.I., Thuresson, M., Jäger, L., Sood, M.M., VanPottelbergh, G., Tangri, N.: Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2.4 million patients from 11 countries: The CaReMe CKD study. *The Lancet Regional Health - Europe*. 20, 100438 (2022). <https://doi.org/10.1016/j.lanepe.2022.100438>
 14. NEW GLOBAL KIDNEY HEALTH REPORT SHEDS LIGHT ON CURRENT CAPACITY AROUND THE WORLD TO DELIVER KIDNEY CARE.
 15. Wu, M.Y., Wu, M.S.: Taiwan renal care system: A learning health-care system. *Nephrology*. 23, 112–115 (2018). <https://doi.org/10.1111/NEP.13460>
 16. Wen, C.P., Cheng, T.Y.D., Tsai, M.K., Chang, Y.C., Chan, H.T., Tsai, S.P., Chiang, P.H., Hsu, C.C., Sung, P.K., Hsu, Y.H., Wen, S.F.: All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. *The Lancet*. 371, 2173–2182 (2008). [https://doi.org/10.1016/S0140-6736\(08\)60952-6](https://doi.org/10.1016/S0140-6736(08)60952-6)
 17. Bikbov, B., Purcell, C.A., Levey, A.S., Smith, M., Abdoli, A., Abebe, M., Adebayo, O.M., Afarideh, M., Agarwal, S.K., Agudelo-Botero, M., Ahmadian, E., Al-Aly, Z., Alipour, V., Almasi-Hashiani, A., Al-Raddadi, R.M., Alvis-Guzman, N., Amini, S., Andrei, T., Andrei, C.L., Andualem, Z., Anjomshoa, M., Arabloo, J., Ashagre, A.F., Asmelash, D., Ataro, Z., Atout, M.M. d. W., Ayanore, M.A., Badawi, A., Bakhtiari, A., Ballew, S.H., Balouchi, A., Banach, M., Barquera, S., Basu, S., Bayih, M.T., Bedi, N., Bello, A.K., Bensenor, I.M., Bijani, A., Bloor, A., Borzi, A.M., Cámara, L.A., Carrero, J.J., Carvalho, F., Castro, F., Catalá-López, F., Chang, A.R., Chin, K.L., Chung, S.C., Cirillo, M., Cousin, E., Dandonna, L., Dandonna, R., Daryani, A., Das Gupta, R., Demeke, F.M., Demoz, G.T., Desta, D.M., Do, H.P., Duncan, B.B., Eftekhari, A., Esteghamati, A., Fatima, S.S., Fernandes, J.C., Fernandes, E., Fischer, F., Freitas, M., Gad, M.M., Gebremeskel, G.G., Gebresillassie, B.M., Geta, B., Ghafourifard, M., Ghajar, A., Ghith, N., Gill, P.S., Ginawi, I.A., Gupta, R., Hafezi-Nejad, N., Haj-Mirzaian, A., Haj-Mirzaian, A., Hariyani, N., Hasan, M., Hasankhani, M., Hasanzadeh, A., Hassen, H.Y., Hay, S.I., Heidari, B., Herteliu, C., Hoang, C.L., Hosseini, M., Hostiu, M., Irvani, S.S.N., Islam, S.M.S., Jafari Balalami, N., James, S.L., Jassal, S.K., Jha, V., Jonas, J.B., Joukar, F., Jozwiak, J.J., Kabir, A., Kahsay, A., Kasaeian, A., Kassa, T.D., Kassaye, H.G., Khader, Y.S., Khalilov, R., Khan, E.A., Khan, M.S., Khang, Y.H., Kisa, A., Kovesdy, C.P., Kuate Defo, B., Kumar, G.A., Larsson, A.O., Lim, L.L., Lopez, A.D., Lotufo, P.A., Majeed, A., Malekzadeh, R., März, W., Masaka, A., Meheretu, H.A.A., Miazgowski, T., Mirica, A., Mirrakhimov, E.M., Mithra, P., Moazen, B., Mohammad, D.K., Mohammadpourhodki, R., Mohammed, S., Mokdad, A.H., Morales, L., Moreno Velasquez, I., Mousavi, S.M., Mukhopadhyay, S., Nachega, J.B., Nadkarni, G.N., Nansseu, J.R., Natarajan, G., Nazari, J., Neal, B., Negoi, R.I., Nguyen, C.T., Nikbakhsh, R., Noubiap, J.J., Nowak, C., Olagunju, A.T., Ortiz, A., Owolabi, M.O., Palladino, R., Pathak, M., Poustchi, H., Prakash, S., Prasad, N., Rafiei, A., Raju, S.B., Ramezanzadeh, K., Rawaf, S., Rawaf,

- D.L., Rawal, L., Reiner, R.C., Rezapour, A., Ribeiro, D.C., Roeber, L., Rothenbacher, D., Rwegerera, G.M., Saadatagah, S., Safari, S., Sahle, B.W., Salem, H., Sanabria, J., Santos, I.S., Sarveazad, A., Sawhney, M., Schaeffner, E., Schmidt, M.I., Schutte, A.E., Sepanlou, S.G., Shaikh, M.A., Sharafi, Z., Sharif, M., Sharifi, A., Silva, D.A.S., Singh, J.A., Singh, N.P., Sisay, M.M.M., Soheili, A., Sutradhar, I., Teklehaimanot, B.F., Tesfay, B. etsy, Teshome, G.F., Thakur, J.S., Tonelli, M., Tran, K.B., Tran, B.X., Tran Ngoc, C., Ullah, I., Valdez, P.R., Varughese, S., Vos, T., Vu, L.G., Waheed, Y., Werdecker, A., Wolde, H.F., Wondmieneh, A.B., Wulf Hanson, S., Yamada, T., Yeshaw, Y., Yonemoto, N., Yusefzadeh, H., Zaidi, Z., Zaki, L., Zaman, S. Bin, Zamora, N., Zarghi, A., Zewdie, K.A., Ämrlöv, J., Coresh, J., Perico, N., Remuzzi, G., Murray, C.J.L.: Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet*. 395, 709–733 (2020). [https://doi.org/10.1016/S0140-6736\(20\)30045-3](https://doi.org/10.1016/S0140-6736(20)30045-3)
18. Lai, T.S., Hsu, C.C., Lin, M.H., Wu, V.C., Chen, Y.M.: Trends in the incidence and prevalence of end-stage kidney disease requiring dialysis in Taiwan: 2010–2018. *Journal of the Formosan Medical Association*. 121, S5–S11 (2022). <https://doi.org/10.1016/J.JFMA.2021.12.013>
 19. Wang, H.S., Yi, M.Y., Wu, X., Liu, Q., Deng, Y.H., Wu, T., Wang, L., Kang, Y.X., Luo, X.Q., Yan, P., Wang, M., Duan, S. Bin: Effects of mesenchymal stem cells in renovascular disease of preclinical and clinical studies: a systematic review and meta-analysis. *Scientific Reports* 2022 12:1. 12, 1–15 (2022). <https://doi.org/10.1038/s41598-022-23059-2>
 20. Zhou, T., Liao, C., Li, H.Y., Lin, W., Lin, S., Zhong, H.: Efficacy of mesenchymal stem cells in animal models of lupus nephritis: A meta-analysis. *Stem Cell Res Ther*. 11, 1–10 (2020). <https://doi.org/10.1186/S13287-019-1538-9/FIGURES/6>
 21. Xia, Y., Ye, H., Li, K., Shi, B., Sun, X., Wu, J.: Efficacy of Mesenchymal Stem Cell Therapy on Lupus Nephritis and Renal Function in Systemic Lupus Erythematosus: A Meta-Analysis. *Clinical and Investigative Medicine*. 46, E24-35 (2023). <https://doi.org/10.25011/CIM.V46I1.39561>
 22. Zhao, S., Li, W., Yu, W., Rao, T., Li, H., Ruan, Y., Yuan, R., Li, C., Ning, J., Li, S., Chen, W., Cheng, F., Zhou, X.: Exosomal miR-21 from tubular cells contributes to renal fibrosis by activating fibroblasts via targeting PTEN in obstructed kidneys. *Theranostics*. 11, 8660–8673 (2021). <https://doi.org/10.7150/thno.62820>
 23. Liu, Y., Guo, Y., Bao, S., Huang, H., Liu, W., Guo, W.: Bone marrow mesenchymal stem cell-derived exosomal microRNA-381-3p alleviates vascular calcification in chronic kidney disease by targeting NFAT5. *Cell Death Dis*. 13, (2022). <https://doi.org/10.1038/s41419-022-04703-1>
 24. Wang, Y., Guo, Y.F., Fu, G.P., Guan, C., Zhang, X., Yang, D.G., Shi, Y.C.: Protective effect of miRNA-containing extracellular vesicles derived from mesenchymal stromal cells of old rats on renal function in chronic kidney disease. *Stem Cell Res Ther*. 11, (2020). <https://doi.org/10.1186/s13287-020-01792-7>


25. Li, D., Qu, J., Yuan, X., Zhuang, S., Wu, H., Chen, R., Wu, J., Zhang, M., Ying, L.: Mesenchymal Stem Cells Alleviate Renal Fibrosis and Inhibit Autophagy via Exosome Transfer of miRNA-122a. *Stem Cells Int.* 2022, (2022). <https://doi.org/10.1155/2022/1981798>
26. Pomatto, M.A.C., Gai, C., Bussolati, B., Camussi, G.: Extracellular vesicles in renal pathophysiology. *Front Mol Biosci.* 4, 269898 (2017). <https://doi.org/10.3389/FMOLB.2017.00037/BIBTEX>
27. Karpman, D., Ståhl, A.L., Arvidsson, I.: Extracellular vesicles in renal disease. *Nature Reviews Nephrology* 2017 13:9. 13, 545–562 (2017). <https://doi.org/10.1038/nrneph.2017.98>
28. Lv, L.-L., Feng, Y., Tang, T.-T., Liu, B.-C., Lin-Li Lv, C., Hospital, Z.: New insight into the role of extracellular vesicles in kidney disease. *J Cell Mol Med.* 23 (2019). <https://doi.org/10.1111/jcmm.14101>
29. Kim, D.K., Lee, J., Kim, S.R., Choi, D.S., Yoon, Y.J., Kim, J.H., Go, G., Nhung, D., Hong, K., Jang, S.C., Kim, S.H., Park, K.S., Kim, O.Y., Park, H.T., Seo, J.H., Aikawa, E., Baj-Krzyworzeka, M., Van Balkom, B.W.M., Belting, M., Blanc, L., Bond, V., Bongiovanni, A., Borràs, F.E., Buée, L., Buzás, E.I., Cheng, L., Clayton, A., Cocucci, E., Dela Cruz, C.S., Desiderio, D.M., Di Vizio, D., Ekström, K., Falcon-Perez, J.M., Gardiner, C., Giebel, B., Greening, D.W., Christina Gross, J., Gupta, D., Hendrix, A., Hill, A.F., Hill, M.M., Nolte-'T Hoen, E., Hwang, D.W., Inal, J., Jagannadham, M. V., Jayachandran, M., Jee, Y.K., Jørgensen, M., Kim, K.P., Kim, Y.K., Kislinger, T., Lässer, C., Lee, D.S., Lee, H., Van Leeuwen, J., Lener, T., Liu, M.L., Lötvall, J., Marcilla, A., Mathivanan, S., Möller, A., Morhayim, J., Mullier, F., Nazarenko, I., Nieuwland, R., Nunes, D.N., Pang, K., Park, J., Patel, T., Pocsfalvi, G., Del Portillo, H., Putz, U., Ramirez, M.I., Rodrigues, M.L., Roh, T.Y., Royo, F., Sahoo, S., Schiffelers, R., Sharma, S., Siljander, P., Simpson, R.J., Soekmadji, C., Stahl, P., Stensballe, A., Stepień, E., Tahara, H., Trummer, A., Valadi, H., Vella, L.J., Wai, S.N., Witwer, K., Yáñez-Mó, M., Youn, H., Zeidler, R., Gho, Y.S.: EVpedia: a community web portal for extracellular vesicles research. *Bioinformatics.* 31, 933–939 (2015). <https://doi.org/10.1093/BIOINFORMATICS/BTU741>
30. O'Brien, J., Hayder, H., Zayed, Y., Peng, C.: Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. *Front Endocrinol (Lausanne).* 9, 402 (2018). <https://doi.org/10.3389/FENDO.2018.00402>
31. Panda, B., Sharma, Y., Gupta, S., Mohanty, S.: Mesenchymal Stem Cell-Derived Exosomes as an Emerging Paradigm for Regenerative Therapy and Nano-Medicine: A Comprehensive Review. *Life.* 11, (2021). <https://doi.org/10.3390/LIFE11080784>
32. Reinders, M.E.J., de Fijter, J.W., Roelofs, H., Bajema, I.M., de Vries, D.K., Schaapherder, A.F., Claas, F.H.J., van Miert, P.P.M.C., Roelen, D.L., van Kooten, C., Fibbe, W.E., Rabelink, T.J.: Autologous Bone Marrow-Derived Mesenchymal Stromal Cells for the Treatment of Allograft Rejection After Renal Transplantation: Results of a Phase I Study. *Stem Cells Transl Med.* 2, 107–111 (2013). <https://doi.org/10.5966/SCTM.2012-0114>

33. Nowak, N., Yamanouchi, M., Satake, E.: The Nephroprotective Properties of Extracellular Vesicles in Experimental Models of Chronic Kidney Disease: a Systematic Review. *Stem Cell Rev Rep.* 18, 902–932 (2022). <https://doi.org/10.1007/S12015-021-10189-9/TABLES/2>
34. Lu, Y., Zhang, R., Gu, X., Wang, X., Xi, P., Chen, X.: Exosomes from tubular epithelial cells undergoing epithelial-to-mesenchymal transition promote renal fibrosis by M1 macrophage activation. *FASEB Bioadv.* 5, 101–113 (2023). <https://doi.org/10.1096/fba.2022-00080>
35. Wang, Z., Yu, Y., Jin, L., Tan, X., Liu, B., Zhang, Z., Wang, Z., Long, C., Shen, L., Wei, G., He, D.: HucMSC exosomes attenuate partial bladder outlet obstruction-induced renal injury and cell proliferation via the Wnt/ β -catenin pathway. *Eur J Pharmacol.* 952, (2023). <https://doi.org/10.1016/j.ejphar.2023.175523>
36. Liu, Y., Guo, W., Guo, Y., Chen, X., Liu, W.: Bone marrow mesenchymal stem cell-derived exosomes improve renal fibrosis via regulating Smurf 2/Smad 7. *Frontiers in Bioscience - Landmark.* 27, (2022). <https://doi.org/10.31083/j.fbl2701017>
37. Alasmari, W.A., Abdelfattah-Hassan, A., El-Ghazali, H.M., Abdo, S.A., Ibrahim, D., Elsayy, N.A., El-Shetry, E.S., Saleh, A.A., Abourehab, M.A.S., Mahfouz, H.: Exosomes Derived from BM-MSCs Mitigate the Development of Chronic Kidney Damage Post-Menopause via Interfering with Fibrosis and Apoptosis. *Biomolecules.* 12, (2022). <https://doi.org/10.3390/biom12050663>
38. Liang, M., Zhang, D., Zheng, D., He, W., Jin, J.: Exosomes from miR-374a-5p-modified mesenchymal stem cells inhibit the progression of renal fibrosis by regulating MAPK6/MK5/YAP axis. *Bioengineered.* 13, 4517–4527 (2022). <https://doi.org/10.1080/21655979.2022.2033465>
39. Zhao, M., Yang, B., Li, L., Si, Y., Chang, M., Ma, S., Li, R., Wang, Y., Zhang, Y.: Efficacy of Modified Huangqi Chifeng decoction in alleviating renal fibrosis in rats with IgA nephropathy by inhibiting the TGF- β 1/Smad3 signaling pathway through exosome regulation. *J Ethnopharmacol.* 285, (2022). <https://doi.org/10.1016/j.jep.2021.114795>
40. Zheng, H., Ji, J., Zhao, T., Wang, E., Zhang, A.: Exosome-encapsulated miR-26a attenuates aldosterone-induced tubulointerstitial fibrosis by inhibiting the CTGF/SMAD3 signaling pathway. *Int J Mol Med.* 51, (2023). <https://doi.org/10.3892/ijmm.2022.5214>
41. Yea, J.H., Yoon, Y.M., Lee, J.H., Yun, C.W., Lee, S.H.: Exosomes isolated from melatonin-stimulated mesenchymal stem cells improve kidney function by regulating inflammation and fibrosis in a chronic kidney disease mouse model. *J Tissue Eng.* 12, (2021). <https://doi.org/10.1177/20417314211059624>
42. Wang, Y., Guo, Y.F., Fu, G.P., Guan, C., Zhang, X., Yang, D.G., Shi, Y.C.: Protective effect of miRNA-containing extracellular vesicles derived from mesenchymal stromal cells of old rats on renal function in chronic kidney disease. *Stem Cell Res Ther.* 11, (2020). <https://doi.org/10.1186/s13287-020-01792-7>

43. Yin, D., Cao, J.Y., Yang, Y., Li, Z.T., Liu, H., Tang, T.T., Ni, W.J., Zhang, Y.L., Jiang, W., Wen, Y., Li, Z.L., Zhao, J., Lv, L.L., Liu, B.C., Wang, B.: Quercetin alleviates tubulointerstitial inflammation by inhibiting exosomes-mediated crosstalk between tubular epithelial cells and macrophages. *Inflammation Research*. 72, 1051–1067 (2023). <https://doi.org/10.1007/s00011-023-01730-2>
44. Liu, X., Liu, Z., Wang, C., Miao, J., Zhou, S., Ren, Q., Jia, N., Zhou, L., Liu, Y.: Kidney tubular epithelial cells control interstitial fibroblast fate by releasing TNFAIP8-encapsulated exosomes. *Cell Death Dis.* 14, (2023). <https://doi.org/10.1038/s41419-023-06209-w>
45. 2020 Exosomes released by human umbilical cord mesenchymal stem cells protect against renal interstitial fibrosis through ROS mediated P38MAPK ERK signaling pathway.
46. Liu, X., Miao, J., Wang, C., Zhou, S., Chen, S., Ren, Q., Hong, X., Wang, Y., Hou, F.F., Zhou, L., Liu, Y.: Tubule-derived exosomes play a central role in fibroblast activation and kidney fibrosis. *Kidney Int.* 97, 1181–1195 (2020). <https://doi.org/10.1016/j.kint.2019.11.026>
47. Wan, Y., Yu, Y., Yu, C., Luo, J., Wen, S., Shen, L., Wei, G., Hua, Y.: Human umbilical cord mesenchymal stem cell exosomes alleviate acute kidney injury by inhibiting pyroptosis in rats and NRK-52E cells. *Ren Fail.* 45, (2023). <https://doi.org/10.1080/0886022X.2023.2221138>
48. Jin, J., Qian, F., Zheng, D., He, W., Gong, J., He, Q.: Mesenchymal stem cells attenuate renal fibrosis via exosomes-mediated delivery of microRNA let-7i-5p antagomir. *Int J Nanomedicine.* 16, 3565–3578 (2021). <https://doi.org/10.2147/IJN.S299969>
49. Liu, L., Wu, Y., Wang, P., Shi, M., Wang, J., Ma, H., Sun, D.: PSC-MSC-Derived Exosomes Protect against Kidney Fibrosis In Vivo and In Vitro through the SIRT6/ β -Catenin Signaling Pathway. *Int J Stem Cells.* 14, 310–319 (2021). <https://doi.org/10.15283/IJSC20184>
50. Wang, H., Wang, B., Zhang, A., Hassounah, F., Seow, Y., Wood, M., Ma, F., Klein, J.D., Price, S.R., Wang, X.H.: Exosome-Mediated miR-29 Transfer Reduces Muscle Atrophy and Kidney Fibrosis in Mice. *Molecular Therapy.* 27, 571–583 (2019). <https://doi.org/10.1016/j.ymthe.2019.01.008>
51. PRISMA, <http://www.prisma-statement.org/?AspxAutoDetectCookieSupport=1>
52. Wang, H., Wang, B., Zhang, A., Hassounah, F., Seow, Y., Wood, M., Ma, F., Klein, J.D., Price, S.R., Wang, X.H.: Exosome-Mediated miR-29 Transfer Reduces Muscle Atrophy and Kidney Fibrosis in Mice. *Molecular Therapy.* 27, 571–583 (2019). <https://doi.org/10.1016/j.ymthe.2019.01.008>
53. Liang, M., Zhang, D., Zheng, D., He, W., Jin, J.: Exosomes from miR-374a-5p-modified mesenchymal stem cells inhibit the progression of renal fibrosis by regulating MAPK6/MK5/YAP axis. *Bioengineered.* 13, 4517–4527 (2022). <https://doi.org/10.1080/21655979.2022.2033465>

54. Jiang, H., Li, J., Yu, K., Yang, H., Min, X., Chen, H., Wu, T.: Associations of estimated glomerular filtration rate and blood urea nitrogen with incident coronary heart disease: the Dongfeng-Tongji Cohort Study. *Scientific Reports* 2017 7:1. 7, 1–9 (2017). <https://doi.org/10.1038/s41598-017-09591-6>
55. Du, S., Guan, Y., Xie, A., Yan, Z., Gao, S., Li, W., Rao, L., Chen, X., Chen, T.: Extracellular vesicles: a rising star for therapeutics and drug delivery. *Journal of Nanobiotechnology* 2023 21:1. 21, 1–51 (2023). <https://doi.org/10.1186/S12951-023-01973-5>
56. Baek, G., Choi, H., Kim, Y., Lee, H.C., Choi, C.: Mesenchymal Stem Cell-Derived Extracellular Vesicles as Therapeutics and as a Drug Delivery Platform. *Stem Cells Transl Med.* 8, 880–886 (2019). <https://doi.org/10.1002/SCTM.18-0226>

Figure 1: Study selection process according to PRISMA.



S. No	Id no.	Location	Source	Autologous/allogeneic	Study type	Phase	Number of patients	Administration frequency	Start year	End year	Status	Outcome measures
1.	NCT05362786	United States	Bone marrow-derived mesenchymal stem cell	Allogenic	Non-randomized, open label	Phase I	14	I.V. injection, delivered MSC in one of two fixed dosing regimens at two time points	2022	N/A	Active, not recruiting	- Primary: adverse events and/or serious adverse events and change in Gfr value
2.	NCT05512988	China	Umbilical cord derived mesenchymal stem cells (UC-MSC)	Autologous	Randomized, double-blind, controlled clinical study	Phase I phase II	44	IV injection, each trial group received two injections throughout the entire course, with a cumulative dose of 2×10^6 cells/kg/person.	2021	N/A	Recruiting	N/A
3.	NCT03321942	China	Adipose-derived mesenchymal stem/stromal cells (MSC)	N/A	Randomized, open label	N/A	100	Intravenous injection for 3 months	2017	N/A	Unknown status	- Primary: mass formation & creatinin - Secondary: Gfr
4.	NCT02166489	Iran	Bone marrow-derived mesenchymal stem cell	Autologous	Open label	Phase I	6	I.V. injection of high doses (2×10^6) of autologous MSC per Kg of their body weight, sourced from bone marrow biopsies.	2014	2016	Completed	- Primary: mass formation - Secondary: Gfr
5.	NCT05042206	Korea	Allogeneic bone marrow derived mesenchymal stem	Allogeneic	Open label, single center	Phase I	10	I.V. injection of 10ml dose 3 times in 2 weeks.	2021	N/A	Unknown status	- Primary: adverse event - Secondary: changes in EGfr, bun and creatinine
6.	NCT03939741	Bangladesh	Adipose derived stem cell (ADSC)	Autologous	Randomized, double-blind, controlled, open label	Phase I/ phase II	31	I.V. injection of 5ml stromal vascular fraction (SVF) containing ADSC.	2019	N/A	Recruiting	- Primary: change of Gfr & adverse events, - Secondary: Iga, igg, igm, c3, c4, crp, il-6, peripheral hemolymocyte subsets.

Table 1: Clinical trials of MSCs in treating chronic kidney diseases.

Abbreviations: N/A: not applicable; I.V.: intravenous

Table 2: Characteristics of included preclinical studies for meta-analysis

Author's name	Country	Year	Animal Model	Sex	Human / Animal	Exosome source	Passage number	Characterization	Isolation method	Exosome size	Exosome marker	Induced method	Concentration	Exosome admin.	End point	Outcome	Ref.
Haidong Wang et al.	USA	2019	C57BL/6 mice	N/A	Animal	Primary mouse satellite cells	P2	NTA	Centrifugation + Filtration	91 ± 1.9 nm	Tsg101	I.M.	N/A	3 rd day	14 days after injection	Exo/miR29 improves skeletal muscle atrophy and reduces kidney fibrosis by suppressing YY1 and TGF-β pathway proteins.	[50]
Qi Liu et al.	USA	2019	C57BL/6 mice	Male	Human	HKC-8	N/A	TEM	Ultracentrifugation	30 to 100 nm	CD63 & TSG101	I.V.	20 mg/kg	1 st day	11 th day after injection	Tubule-derived exosomes contribute to renal fibrogenesis by transporting Sonic Hedgehog (Shh) ligand.	[46]
Bo Liu et al.	China	2020	SD rats	Male	Human	hUCMSCs	P3	TEM	Centrifugation + Filtration	50-100 nm	CD9, CD63 & CD81	I.C.	200 µg	N.A.	14 th day after injection.	HucMSC-Ex attenuated UO-induced renal fibrosis and tubular cell apoptosis by inhibiting the ROS-mediated p38MAPK/ERK signaling pathway.	[45]
Yan Wang et al.	China	2020	Bred Fisher rats	N/A	Animal	BM-MSCs	P2	N/A	Centrifugation + Filtration	N/A	CD44, CD29 & alpha 4-integrin	I.V.	N/A	0 day	14 th day after injection.	MiR-294/miR-133 overexpression prevented TGF-β1-induced epithelial-mesenchymal transition in HK2 cells by inhibiting SMAD2/3 and ERK1/2 phosphorylation.	[42]
Mingmin Zhao et al.	China	2021	SD Rats	N/A	Animal	Rat urine sample	N/A	TEM, NTA	Ultracentrifugation	30–150 nm	CD63, CD81 & calnexin	I.V.	12.50 g/kg	N.A.	18 weeks after injection	MHCD mitigated renal fibrosis in IgA nephropathy rats by suppressing the TGF-β1/Smad3 pathway through exosomal downregulation of TGF-β1 expression.	[39]
Huan Jin et al.	China	2021	C57BL/6 mice	Female	Human	BM-MSCs	N/A	TEM, NTA	Exosome Isolation Kit	50–150 nm	CD 9, CD 81	I.V.	50 µg	Twice a week	28 th day	MSC exosomal anti-let-7i-5p combats TGF-β1-induced fibrosis in NRK52E cells and UO-induced renal fibrosis in vivo.	[48]
Jimin Liu et al.	China	2021	C57BL/6 mice	Male	Human	PSC-MSCs	P3~8	NTA	Centrifugation + Filtration	10~150 nm	CD90, CD45, CD105 & CD19	I.V.	1×10 ¹¹ (Particle amount)	N.A.	14 th day after injection.	Upregulating SIRT6 expression while downregulating β-catenin and its downstream products.	[49]
Ji H. Lee et al.	S. Korea	2021	BALB/c mice	Male	Human	AD-MSC	P2	TEM, NTA	Exosome isolation kit	173.02 ± 2.34 nm	CD81 & CD9	I.V.	100 µg	twice a week for 2 weeks	3 rd week after administration	Exocue treatment downregulated CKD-related miRNAs, improving kidney function via aquaporin upregulation and reduced	[41]

																urea and creatinine levels.	
Yingjie Liu et al.	China	2022	SD rats	Male	Human	BM-MSCs	P4~6	TEM, NTA	Centrifugation + Filtration	30–150 nm	CD9, CD63, & CD81	I.V.	150 µg/week	Once a week	16 th week	BMSC-Exo strengthened si-Smurf2's protective effect against TGF-β1-induced fibrosis.	[36]
Hui Zheng et al.	China	2022	C57BL/6 mice	Male	Human	293 cell line human embryonic kidney cells	N/A	TEM	Ultracentrifugation	100 nm	CD63, CD81 & Alix	I.V.	100 µg	Once a week	28 th day	Exo-miR-26a relieved kidney-downregulated miR-26a expression, tubular injury, and aldosterone (ALD)-induced TIF.	[40]
V. A. Alasmari et al.	Saudi Arabia	2022	Albino rats	Female	Animal	BM-MSCs	P3	TEM	Centrifugation + Filtration	70 nm	CD63, CD81	I.V.	100 µg	24 h after ovariectomy	8 th week	Exosomes hinder CKD progression by lowering gene expression of NGAL, TGF-β1, and α-SMA.	[37]
Mingzhu Jiang et al.	China	2022	C57BL/6 mice	N/A	Human	HK-2 cells proximal tubular cell line	N/A	TEM, NTA	Centrifugation + Filtration	100 to 150 nm	CD63 & TSG101	I.V.	N/A	twice weekly for 4 weeks	28 th day	MiR-374a-5p hinders renal fibrosis progression by modulating the MAPK6/MK5/YAP axis.	[38]
Yueqing Liu et al.	China	2023	BALB/c mice	Male	Animal	Mouse renal tubular cell line TCMK-1	N/A	TEM	Ultracentrifugation	145.8 nm	HSP70, CD63, & TSG-101	I.V.	100 µg	Per day for 5 days	7 th day	TGF-β-induced TECs co-cultured with macrophages led to M1 polarization. Exosomes from TECs without TGF-β or with TGF-β alone did not induce M1 macrophage markers.	[34]
Zhaoying Wang et al.	China	2023	C57BL/6 mice	Male	Human	hucMSCs	N/A	TEM, NTA	Ultracentrifugation	30–150 nm	CD63, Tsg101, & Alix	I.V.	100 µg	Once 7 days after surgery	14 th day	Inhibited expression of proteins related to the Wnt/β-catenin signaling pathway.	[35]
Zonghon ; Wan et al.	China	2023	SD Rats	Male	Human	hucMSCs	P5	TEM, NTA	Ultracentrifugation	30–150 nm	CD63, Tsg101, & Alix	I.V.	250 µg	Immediately after reperfusion	24 hrs after injection	HucMSC-Ex reduced pyroptosis-related proteins (NLRP3, GSDMD, caspase-1, and IL-1β) in renal tissue of IRI rats.	[47]
Qi Liu et al.	China	2023	C57BL/6 mice	Male	Human	HKC-8	N/A	TEM, NTA	Ultracentrifugation	30–150 nm	CD63, Tsg101	I.V.	200 µg	Once in 2 days	14 th day	Exo-TNFAIP8 promotes fibroblast survival by inducing p53 degradation and stimulating proliferation.	[44]
Ji Yin et al.	China	2023	C57BL/6 mice	Male	Animal	Tubular epithelial cells of mouse	N/A	TEM, NTA	Ultracentrifugation	129.5 ± 8.2 nm	CD63, CD9, TSG101, & Alix	I.P.	200 µg	Once on day 1	3 rd day	Quercetin inhibits exosome release, exerting renoprotective effects by suppressing Hsp70 or Hsp90.	[43]

Abbreviations: N/A: not applicable; I.V.: intravenous; IM: Intramuscular; I.C: Intracellular; IP: Intraparietal; HKC-8: Human proximal tubular epithelial cells; HbMSCs: Human bone marrow derived; hucMSCs: Human umbilical cord mesenchymal stem cells; AD: Human adipose; PSC-MSCs: pluripotent stem cell-derived mesenchymal stem cells.

	Selection of articles (Selection bias)	Selective reporting (reporting bias)	Deviation from intended intervention (Performance bias)	Binding of outcome assessment (Detection bias)	Incomplete outcome data (Attrition bias)	Baseline characteristics	Other bias	
Di Yin et al. (2023)	+	+	+	+	+	+	+	+
Xi Liu et al. (2023)	+	+	+	+	-	+	+	+
Y. Wan et al. (2023)	+	+	+	+	+	+	+	+
Z. Wang et al. (2023)	+	+	+	+	+	+	+	+
Yuqing Lu et al. (2023)	+	+	+	+	+	+	+	+
M. Liang et al. (2022)	+	+	+	+	+	?	+	+
W. A. Alasmari et al. (2022)	+	+	+	+	+	+	+	+
Hui Zheng et al. (2022)	+	+	+	+	+	+	+	+
Yingjie Liu et al. (2022)	+	+	+	+	-	+	+	+
Limin Liu et al. (2021)	+	+	+	+	+	+	+	+
Juan Jin et al. (2021)	+	+	+	+	+	+	+	+
Ji. H. Yea et al. (2021)	+	+	+	+	+	+	+	+
Mingming Zhao et al. (2021)	+	+	+	+	+	+	+	+
Yan Wang et al. (2020)	+	+	+	+	+	?	?	+
Bo Liu et al. (2020)	+	+	+	+	+	+	+	+
Xi Liu et al. (2019)	+	+	+	+	+	+	+	+
H. Wang et al. (2019)	+	+	+	+	-	?	+	+

 Low risk of bias
 High risk of bias
 Under risk of bias

Figure 2: Risk of BIAS





Figure 3: BUN and SCR level expressed with their 95% confidence intervals (A) efficacy in BUN reduction of MSC derived EXOs in the CKD model (B) efficacy in SCR reduction of MSC derived EXOs in the CKD model.







Figure 4: Subgroup analysis based on animal model with their 95% confidence intervals (A) efficacy in BUN reduction of MSC derived EXOs (B) efficacy in SCR reduction of MSC derived EXOs.

Graphical abstract



Graphical highlight:

1. MSC-EXOs show promise in improving renal function and reducing CKD risk, as evidenced by comprehensive meta-analysis findings.
2. Pooled proportions indicate significant associations between MSC-EXO treatment and reduced BUN and SCR levels and increased GFR rate, highlighting their potential therapeutic efficacy.
3. Exosomes show a significant effect on renal function, as indicated by the study findings.